It was inevitable that local governments would make way for Colorado’s terribly misguided experiment with newly legalized ...

The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down. Emerson has ...

Lykos Therapeutics is slashing around 75% of its staff following the FDA's decision not to approve its MDMA-assisted therapy for post-traumatic stress disorder (PTSD) last week, with founder Rick ...

Lykos Metals Limited (AU:LYK) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - ...

Researchers will use AI to analyze patient data from audio, video and biometric sensors, then develop a virtual counselor to ...

The FDA has previously acknowledged its therapeutic potential, granting a new drug application, submitted by Lykos Therapeutics (formerly MAPS Public Benefit Corporation), priority review for ...

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits ...

The Senate Study Committee on Veterans' Mental Health and Housing urged lawmakers to allocate $5 million to research drugs ...

The treatment, developed by Lykos Therapeutics, is a pharmaceutical version of midomafetamine, better known as MDMA and sometimes referred to as ecstasy. The Psychopharmacologic Drugs Advisory ...

Click here for a full investment analysis of Cybin Inc., a speculative play on FDA approval for psychedelic-based treatments.

An FDA advisory panel voted against recommending the use of MDMA in PTSD therapy. The rejection of Lykos Therapeutics' treatment hurt stocks of firms with similar therapies in development.

Lykos Metals Limited announced the appointment of David Wheeler as a director, effective from November 27, 2024. Wheeler currently holds no securities or relevant interests in the company ...